Meridian Bioscience in midst of clinical trials for two molecular tests
Meridian Bioscience‘s (NASDAQ:VIVO) has two molecular diagnostic tests in clinical trials, with another test expected to begin trials later in the year. Currently in trials are tests built on the company’s illumigene molecular diagnostic testing platform for Mycoplasma pneumonia, an infection of the lungs, and group A streptococcus, a type of bacteria often found in […]